Lv1
70 积分 2025-10-13 加入
CD40 Agonist Antibodies in Cancer Immunotherapy
17天前
已关闭
Understanding and treating the inflammatory adverse events of cancer immunotherapy
23天前
已关闭
Efficacy of CLDN18.2-Targeted Radiotheranostics in Patient-Derived Models of Gastric Cancer
1个月前
已关闭
Preclinical Evaluation of [¹⁷⁷Lu]Lu-ART-101 for Radiopharmaceutical Therapy of Advanced Prostate Cancer
1个月前
已完结
Preclinical and First-in-Human Study of Carbonic Anhydrase IX-Targeting Theranostic Pair, [68Ga]Ga/[177Lu]Lu-NYM096, in Clear Cell Renal Cell Carcinoma
1个月前
已完结
The Preclinical Pharmacology of Tepotinib—A Highly Selective MET Inhibitor with Activity in Tumors Harboring MET Alterations
4个月前
已完结
Properties of FDA-approved small molecule protein kinase inhibitors: A 2021 update
4个月前
已完结
Capmatinib Could Alter NSCLC Treatment Landscape
5个月前
已关闭
Evolving roles of MET as a therapeutic target in NSCLC and beyond
5个月前
已完结
皖公网安备34019202002308
